Please use this identifier to cite or link to this item: doi:10.22028/D291-41702
Title: Early CRP kinetics to predict long‐term efficacy of first‐line immune‐checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real‐world experience applying different CRP kinetics definitions
Author(s): Hoeh, Benedikt
Garcia, Cristina Cano
Banek, Severine
Klümper, Niklas
Cox, Alexander
Ellinger, Jörg
Schmucker, Philipp
Hahn, Oliver
Mattigk, Angelika
Zengerling, Friedemann
Becker, Philippe
Erdmann, Kati
Buerk, Bjoern Thorben
Flegar, Luka
Huber, Johannes
Kalogirou, Charis
Zeuschner, Philip
Language: English
Title: Clinical & Translational Immunology
Volume: 12
Issue: 10
Publisher/Platform: Wiley
Year of Publication: 2023
Free key words: biomarker
checkpoint inhibition
C-reactive protein
CRP flare-response
first-line therapy
metastatic renal cell carcinoma
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Objectives. Although biomarkers predicting therapy response in first-line metastatic renal carcinoma (mRCC) therapy remain to be defined, C-reactive protein (CRP) kinetics have recently been associated with immunotherapy (IO) response. Here, we aimed to assess the predictive and prognostic power of two contemporary CRP kinetics definitions in a large, real-world first-line mRCC cohort. Methods. Metastatic renal carcinoma patients treated with IO-based first-line therapy within 5 years were retrospectively included in this multicentre study. According to Fukuda et al., patients were defined as ‘CRP flare-responder’, ‘CRP responder’ and ‘non-CRP responder’; according to Ishihara et al., patients were defined as ‘normal’, ‘normalised’ and ‘non-normalised’ based on their early CRP kinetics. Patient and tumor characteristics were compared, and treatment outcome was measured by overall (OS) and progression-free survival (PFS), including multivariable Cox regression analyses. Results. Out of 316 mRCC patients, 227 (72%) were assigned to CRP groups according to Fukuda. Both CRP flare- (HR [Hazard ratio]: 0.59) and CRP responders (HR: 0.52) had a longer PFS, but not OS, than non-CRP responders. According to Ishihara, 276 (87%) patients were assigned to the respective groups, and both normal and normalised patients had a significantly longer PFS and OS, compared with non-normalised group. Conclusion. Different early CRP kinetics may predict therapy response in first-line mRCC therapy in a large real-world cohort. However, further research regarding the optimal timing and frequency of measurement is needed.
DOI of the first publication: 10.1002/cti2.1471
URL of the first publication:
Link to this record: urn:nbn:de:bsz:291--ds-417021
ISSN: 2050-0068
Date of registration: 4-Mar-2024
Description of the related object: Supporting Information
Related object:
Faculty: M - Medizinische Fakultät
Department: M - Urologie und Kinderurologie
Professorship: M - Prof. Dr. Michael Stöckle
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

This item is licensed under a Creative Commons License Creative Commons